HUP9902181A3 - Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action - Google Patents

Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action

Info

Publication number
HUP9902181A3
HUP9902181A3 HU9902181A HUP9902181A HUP9902181A3 HU P9902181 A3 HUP9902181 A3 HU P9902181A3 HU 9902181 A HU9902181 A HU 9902181A HU P9902181 A HUP9902181 A HU P9902181A HU P9902181 A3 HUP9902181 A3 HU P9902181A3
Authority
HU
Hungary
Prior art keywords
acylated
hydroxy methyl
immunomodulator
action
prodrugs
Prior art date
Application number
HU9902181A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of HUP9902181A2 publication Critical patent/HUP9902181A2/hu
Publication of HUP9902181A3 publication Critical patent/HUP9902181A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
HU9902181A 1996-04-09 1997-03-22 Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action HUP9902181A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19613976A DE19613976C1 (de) 1996-04-09 1996-04-09 Thalidomid-Prodrugs mit immunmodulatorischer Wirkung

Publications (2)

Publication Number Publication Date
HUP9902181A2 HUP9902181A2 (hu) 2000-04-28
HUP9902181A3 true HUP9902181A3 (en) 2002-11-28

Family

ID=7790778

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9902181A HUP9902181A3 (en) 1996-04-09 1997-03-22 Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action

Country Status (12)

Country Link
US (1) US6417197B1 (enExample)
EP (1) EP0892794B1 (enExample)
JP (1) JP2000508298A (enExample)
CN (1) CN1102931C (enExample)
AT (1) ATE212989T1 (enExample)
AU (1) AU707144B2 (enExample)
DE (2) DE19613976C1 (enExample)
DK (1) DK0892794T3 (enExample)
ES (1) ES2171923T3 (enExample)
HU (1) HUP9902181A3 (enExample)
PT (1) PT892794E (enExample)
WO (1) WO1997037988A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19613976C1 (de) * 1996-04-09 1997-11-20 Gruenenthal Gmbh Thalidomid-Prodrugs mit immunmodulatorischer Wirkung
CZ389398A3 (cs) * 1996-05-29 1999-07-14 Prototek, Inc. Proléčiva thalidomidu a jejich použití pro modulaci funkce T-buněk
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
DE19743968C2 (de) * 1997-10-06 2002-07-11 Gruenenthal Gmbh Intravenöse Applikationsform von Thalidomid zur Therapie immunologischer Erkrankungen
ES2192342T3 (es) * 1997-11-18 2003-10-01 Celgene Corp 2-(2,6-dioxo-3-fluoropiperidin-3-il)-isoindolinas sustituidas y su uso para reducir los niveles de tnfalfa.
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
AU4515001A (en) * 1999-12-02 2001-06-18 Regents Of The University Of Michigan, The Compositions and methods for locally treating inflammatory diseases
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
EP1389203B8 (en) * 2001-02-27 2010-03-10 The Governement of the United States of America, represented by The Secretary Department of Health and Human services Analogs of thalidomide as angiogenesis inhibitors
CN100488959C (zh) * 2003-03-27 2009-05-20 天津和美生物技术有限公司 水溶性的酞胺哌啶酮衍生物
WO2005016326A2 (en) * 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
CN100398534C (zh) * 2003-09-15 2008-07-02 天津和美生物技术有限公司 合成酞胺哌啶酮及其衍生物的方法
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
WO2005028436A2 (en) 2003-09-17 2005-03-31 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Thalidomide analogs as tnf-alpha modulators
JP4755991B2 (ja) * 2003-10-16 2011-08-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｒａｆキナーゼインヒビターとしての置換ベンゾアゾールおよびその使用
ITMI20041113A1 (it) * 2004-06-01 2004-09-01 Antibioticos Spa Processo per la sintesi della talidomide
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
CA2648216C (en) 2006-04-13 2016-06-07 Michael Gutschow Tetrahalogenated compounds useful as inhibitors of angiogenesis
EP2358697B1 (en) * 2008-10-29 2015-10-21 Celgene Corporation Isoindoline compounds for use in the treatment of cancer.
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
EP3399978B1 (en) * 2016-01-08 2020-09-09 Celgene Corporation Antiproliferative compounds, and their pharmaceutical compositions and uses
US20200199097A1 (en) * 2017-08-21 2020-06-25 Nanjing Noratech Pharmaceuticals Co., Ltd Pomalidomide derivative and preparation method therefor
CN111499610A (zh) * 2019-01-31 2020-08-07 南京诺瑞特医药科技有限公司 泊马度胺前体药物盐的多晶型物
EP3771711A1 (en) 2019-07-29 2021-02-03 Bayer Animal Health GmbH Pyrazole derivatives for controlling arthropods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1531492A (en) * 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
WO1992018496A1 (de) * 1991-04-17 1992-10-29 Grünenthal GmbH Neue thalidomidderivate, ein verfahren zu deren herstellung sowie die verwendung derselben in arzneimitteln
DE19613976C1 (de) * 1996-04-09 1997-11-20 Gruenenthal Gmbh Thalidomid-Prodrugs mit immunmodulatorischer Wirkung

Also Published As

Publication number Publication date
EP0892794B1 (de) 2002-02-06
HUP9902181A2 (hu) 2000-04-28
EP0892794A1 (de) 1999-01-27
US6417197B1 (en) 2002-07-09
PT892794E (pt) 2002-07-31
CN1102931C (zh) 2003-03-12
JP2000508298A (ja) 2000-07-04
WO1997037988A1 (de) 1997-10-16
AU2505297A (en) 1997-10-29
CN1215397A (zh) 1999-04-28
DE59706313D1 (de) 2002-03-21
DE19613976C1 (de) 1997-11-20
DK0892794T3 (da) 2002-04-15
ATE212989T1 (de) 2002-02-15
AU707144B2 (en) 1999-07-01
ES2171923T3 (es) 2002-09-16
HK1017350A1 (en) 1999-11-19

Similar Documents

Publication Publication Date Title
GB9714462D0 (en) Multi-venting molding apparatus
GB2317140B (en) Molded article retrieval apparatus
SI0892794T1 (en) Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action
GB2313870B (en) Enclosure
GB2311090B (en) Enclosure device
PL317885A1 (en) Motor-horn switch enclosure
GB9713860D0 (en) Enclosure component
GB2343409B (en) Improved molded article retrieval apparatus
GB9613380D0 (en) Electro-magnetic pallet stripper
GB2333574B (en) Movement-controlling device
ZA987585B (en) Acylated 5-aminoisothiazoles
PL323271A1 (en) Box
PL325529A1 (en) Deviations eliminating device
GB9607776D0 (en) Moulding removal device
GB2287811B (en) Polling
GB2313080B (en) A stripping device
KR200173933Y1 (en) Micro-switch
TW311331U (en) Improved seedlings-growing box arrangement device
ZA975095B (en) Box
GB9623027D0 (en) Box
AU129906S (en) Bin enclosure
SG75893A1 (en) Clean box
GB9611660D0 (en) Enclosure
TW303793U (en) Modified mold remover structure
TW299703U (en) Improved holding plate

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees